Pharma Company Investment in Parenteral Manufacturing Capacity Picking Up

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-10-02-2004
Volume 28
Issue 10

Big Pharma is ramping up capital spending in parenteral manufacturing at the same time that contract manufacturers are completing their own major investment programs.

External Link - article-128384.pdf

Articles in this issue
A Novel Freeze Pelletization Technique for Preparing Matix Pellets
Aseptic Processing: A Review of Current Industry Practice
Can Inserts Be Improved?
Analysis of a Kneading Process to Evaluate Drug Substance-Cyclodextrin Complexation
Drug Development Linked More Closely to Diagnostics
Preparation and In Vitro Characterization of Self-Nanoemulsified Drug Delivery Systems of Coenzyme Q10 Using Chiral Essential Oil Components
In The Spotlight-October 2004
October 2004
Visible-Residue Limit for Cleaning Validation and its Potential Application in Pharmaceutical Research Facility
The High Price of Success
Pharma Company Investment in Parenteral Manufacturing Capacity Picking Up
USP General Notices and General Test Chapters: Interpretations and Misinterpretations
Breaking the Barrier: Advances in Transdermal Technology
Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Related Content
Movement towards the intended goal. Moving forward, step by step. Labor and aspiration. Motivation, self-development. Business strategic planning, risk management. New opportunities. Achieve. | Image Credit: ©Andrii Yalanskyi – Stock.Adobe.com

Steps to Process Development Optimization

Susan Haigney
February 4th 2025
Article

The optimization of processes for the development and manufacture of biopharmaceuticals is pivotal for producing quality products.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

3d rendering of Antibody drug conjugates (ADCs) are targeted medicines that deliver chemotherapy agents to cancer cells | Image Credit: © Love Employee - © Love Employee- stock.adobe.com

Advancing ADCs to the Next Level

Feliza Mirasol
February 4th 2025
Article

CDMOs who have integrated technologies can help further the advancement of ADC development.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

High Angle Shot of a Working Desk of an Successful Person in Office with Cityscape Window View. | Image credit: © Gorodenkoff - stock.adobe.com

Dealmaking on the Rise?

Mike Hennessy Jr.
January 31st 2025
Article

If the conditions prove optimal, 2025 could be a prosperous year for bio/pharma business deals.

Question mark background | Image Credit: © Leigh-Prather - © Leigh Prather - stock.adobe.com

Regulations in AI and Other Digital Technologies

Siegfried Schmitt
January 31st 2025
Article

AI regulations in healthcare are rapidly evolving, and one should consult with regulatory subject matter experts, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.